The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
about
Mechanisms of Cross-protection by Influenza Virus M2-based VaccinesM2e-Based Universal Influenza A VaccinesInfluenza virus-like particles containing M2 induce broadly cross protective immunityConserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine developmentDevelopment of universal influenza vaccines based on influenza virus M and NP genes.New vaccines against influenza virus.The fight against new types of influenza virus.Synthesis and Immunogenicity Assessment of Elastin-Like Polypeptide-M2e Construct as an Influenza Antigen.Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus.The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.Novel vaccines against influenza viruses.Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.The prospects and challenges of universal vaccines for influenzaSubviral particle as vaccine and vaccine platform.Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice.Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coliImmunization with a MOMP-based vaccine protects mice against a pulmonary Chlamydia challenge and identifies a disconnection between infection and pathologyMucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouseVirus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.The threat of avian influenza A (H5N1). Part IV: Development of vaccines.Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.Virus-like particles containing the tetrameric ectodomain of influenza matrix protein 2 and flagellin induce heterosubtypic protection in mice.Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection.Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.Gold nanoparticle-M2e conjugate coformulated with CpG induces protective immunity against influenza A virus.Towards a Chlamydia trachomatis vaccine: how close are we?Universal vaccines: shifting to one for many or shooting too high too soon!Universal fungal vaccines: could there be light at the end of the tunnel?Hepatitis B core-based virus-like particles to present heterologous epitopes.Recent advancements in combination subunit vaccine development.Production and evaluation of virus-like particles displaying immunogenic epitopes of porcine reproductive and respiratory syndrome virus (PRRSV)DNA-vaccine platform development against H1N1 subtype of swine influenza A viruses.Recombinant Adenoviruses Displaying Matrix 2 Ectodomain Epitopes on Their Fiber Proteins as Universal Influenza Vaccines.M2-based influenza vaccines: recent advances and clinical potential.
P2860
Q26777740-135C5AB2-E4B8-455E-926D-5039BFD73087Q26783493-7C4E0C06-5258-49B2-8803-2321090E5D51Q28743472-D1999A14-1781-4D26-B68C-430A8B228ECBQ30226873-248A0458-3C2D-4F20-81EF-5487A1E420DDQ30355116-D7D2C066-ED00-475A-A086-E53DD7725D42Q30357932-5693E2D9-2FBA-49C0-AB69-A92D486C4649Q30358252-5ED6586F-AD1B-44B2-B837-D172019FE394Q30373251-3A2132F8-1198-409D-8916-6A5031FFFF1FQ30373993-496977F5-168D-4948-998B-2E9252E81B60Q30375991-1C60BC5E-EF3D-4688-A774-C880926ADB88Q30397930-22C95634-A2E8-43A9-92C2-DC84880EC8BEQ30404699-53180985-A20F-4714-82BA-956B6E1804FAQ30407716-929177D4-A454-4C63-B816-4252BF0537C3Q30410241-A6A52882-F02E-4FB8-B4E0-36B7DDECA959Q30430703-BF9AB6A5-DEA0-4F38-ACFA-5C4DDF8AADB0Q33812653-F1C5E874-1AF3-45BB-9187-484BEDE6C537Q34105207-95756D70-F43C-45A4-8C0C-AC906BC046C9Q34533990-6B68D53F-A671-427B-8D08-BB72431553C0Q34685461-69672218-6780-452B-9F6B-A3F10907B90EQ35142923-E6673DE8-E6BB-4CDD-AB7A-D0729C9BD6ABQ35689134-011C6DA8-66D4-4581-86E0-20E445128EC9Q35772241-FE057104-71AB-4E5F-9CC5-DF2D6154931CQ36345130-46A046AE-E190-4F36-B81D-F0B6368E901FQ36673724-A1C0BF8E-C628-4D0E-8013-3ABCF791DCD8Q36727331-E0394E75-1C02-4095-B471-524B6880066AQ36836699-064C0F79-7FAD-4CEF-B9A3-28478F228666Q36977642-626B69EB-A50F-4091-BAFA-BD7EAF8D9C15Q37101184-0E596CC2-2640-45BB-AED3-7A9F18B42F11Q37210056-3AE7105B-4FE0-4781-B4CB-8174C2553CC2Q37627859-61B3C9AE-A390-4C0F-89A4-A813E89551F6Q37645689-3B6FC7CD-4028-479C-8D0E-06673C3C3EB9Q37820669-379C093A-3170-4F38-9F57-68DA48112E7BQ37919551-6E229C1A-E77F-4293-AC03-B9E267CE7E7CQ38038044-80006B25-5D70-46D6-BA3E-C1B970D51479Q38081969-782BA932-AE18-4899-BE35-A70AB8F1C8DFQ38819439-581F0EA9-18A9-4EBC-AAC5-42873BE1AEA7Q38887093-E1B0BB4B-6ED5-4C53-B58A-F9BCED7DAE75Q39311178-12464024-5396-49D5-9C86-19D0163BAEE9Q40366453-80B50875-E54B-49E7-B922-5E60384DB68AQ40571808-BFF37C1E-75D1-4102-B80E-963A9E98A91E
P2860
The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The universal influenza vaccin ...... provides complete protection.
@en
The universal influenza vaccin ...... provides complete protection.
@nl
type
label
The universal influenza vaccin ...... provides complete protection.
@en
The universal influenza vaccin ...... provides complete protection.
@nl
prefLabel
The universal influenza vaccin ...... provides complete protection.
@en
The universal influenza vaccin ...... provides complete protection.
@nl
P2093
P1433
P1476
The universal influenza vaccin ...... provides complete protection.
@en
P2093
Anna Ramne
Ashley Birkett
Björn Löwenadler
Marina De Filette
Walter Fiers
Willy Min Jou
Xavier Saelens
P304
P356
10.1016/J.VACCINE.2005.08.061
P407
P577
2005-08-31T00:00:00Z